Thanks for your skepticism - it is needed when investing.
another view would be that the fact that they knew they were running out of cash made them fight all the more to win the LabCon deal.
I hardly think that LabCon were going to sign up to a 3year deal worth $15M just to suit the timing of BCT and their ideal market timing for a CR. the exclusivIty clause Is confirmatIon of theIr belief in the competItIve advantage the Bct product offering delivers IMO. production volumes of the chIps have been steadily rising so the contract doesn't seem out of kilter with that trajectory.
the annual report presents very confidently that more good things are on the horizon and with the good record of management there is nothing that leads me to doubt at this stage.
DYOR and keep up the critical thoughts...
- Forums
- ASX - By Stock
- BCT
- ASX Today
ASX Today, page-48
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BCT (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.737M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
BCT (ASX) Chart |
Day chart unavailable
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online